PDCD1 and head and neck squamous cell carcinoma: For instance, the KEYNOTE‐40 trial showed that pembrolizumab, a humanized monoclonal antibody targeting PD‐1, improved the median overall survival (OS) duration and, therefore, deemed superior to traditional treatment as the second‐line therapy for R/M head and neck squamous cell carcinoma (HNSCC) [4].